Impact of bronchodilator use on the prevalence of COPD in population-based samples

COPD: Journal of Chronic Obstructive Pulmonary Disease

Volumn 4, Issue 2, 2007, Pages 113-120

  Pérez Padilla, Rogelio ^a   Hallal, Pedro Curi ^b   Vázquez García, Juan Carlos ^a   Muiño, Adriana ^c   Máquez, María ^c   López, María Victorina ^c   De Oca, María Montes ^d   Tálamo, Carlos ^d   Valdivia, Gonzalo ^e   Pertuzé, Julio ^e   Jardim, Jose ^f   Menezes, Ana Maria B ^b  

^a INSTITUTO NACIONAL DE ENFERMEDADES RESPIRATORIAS   (Mexico)

^b FEDERAL UNIVERSITY OF PELOTAS   (Brazil)

^c DEPARTAMENTO DE BIOQUÍMICA   (Uruguay)

^d HOSPITAL UNIVERSITARIO DE CARACAS   (Venezuela)

^e PONTIFICIA UNIVERSIDAD CATÓLICA DE CHILE   (Chile)

^f FEDERAL UNIVERSITY OF SÃO PAULO   (Brazil)

Author keywords

Airflow obstruction; Bronchodilator response; COPD definition; Diagnosis of COPD

Indexed keywords

BRONCHODILATING AGENT; SALBUTAMOL;

ADULT; AGED; AIRWAY OBSTRUCTION; ARTICLE; BRONCHODILATATION; CHRONIC OBSTRUCTIVE LUNG DISEASE; CLUSTER ANALYSIS; CONTROLLED STUDY; DUST; FEMALE; FORCED EXPIRATORY VOLUME; HEALTH SURVEY; HUMAN; INHALATION; MAJOR CLINICAL STUDY; MALE; PREVALENCE; PRIORITY JOURNAL; SMOKING; SPIROMETRY; TOBACCO; AGE; HEALTH; MIDDLE AGED; SOUTH AND CENTRAL AMERICA; STATISTICS; VITAL CAPACITY;

ADULT; AGE FACTORS; AGED; BRONCHODILATOR AGENTS; FEMALE; FORCED EXPIRATORY VOLUME; HUMANS; LATIN AMERICA; MALE; MIDDLE AGED; PREVALENCE; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; SPIROMETRY; URBAN HEALTH; VITAL CAPACITY;

EID: 34547399133     PISSN: 15412555     EISSN: 15412563     Source Type: Journal    
DOI: 10.1080/15412550701341012     Document Type: Article

References (43)

1. GOLD. Workshop report, global strategy for diagnosis, management and prevention of COPD http://www.goldcopd.com/2005.
2. Celli BR, MacNee W. Standards for the diagnosis and treatment of patients with COPD: a summary of the ATS/ERS position paper. Eur Respir J 2004; 23(6):932-946.
3. Pellegrino R, Viegi G, Brusasco V, Crapo RO, Burgos F, Casaburi R, Coates A, van der Grinten CP, Gustafsson P, Hankinson J, Jensen R, Johnson DC, MacIntyre N, McKay R, Miller MR, Navajas D, Pedersen OF, Wanger J. Interpretative strategies for lung function tests. Eur Respir J 2005; 26(5):948-968.
4. Kerstjens HA, Brand PL, Quanjer PH, van der Bruggen-Bogaarts BA, Koeter GH, Postma DS. Variability of bronchodilator response and effects of inhaled corticosteroid treatment in obstructive airways disease. Dutch CNSLD Study Group. Thorax 1993; 48(7):722-729.
5. Jenkins C, Young I. Assessing bronchodilator reversibility: agreed standards are urgently needed. Med J Aust 2004; 180(12):605-606.
6. Dompeling E, van Schayck CP, Molema J, Akkermans R, Folgering H, van Grunsven PM, van Weel C. A comparison of six different ways of expressing the bronchodilating response in asthma and COPD; reproducibility and dependence of prebronchodilator FEV1. Eur Respir J 1992; 5(8):975-981.
7. Brand PL, Quanjer PH, Postma DS, Kerstjens HA, Koeter GH, Dekhuijzen PN, Sluiter HJ. Interpretation of bronchodilator response in patients with obstructive airways disease. The Dutch Chronic Non-Specific Lung Disease (CNSLD) Study Group. Thorax 1992; 47(6):429-436.
8. Chhabra SK. Acute bronchodilator response has limited value in differentiating bronchial asthma from COPD. J Asthma 2005; 42(5):367-372.
9. Kesten S, Rebuck AS. Is the short-termresponse to inhaled betaadrenergic agonist sensitive or specific for distinguishing between asthma and COPD? Chest 1994; 105(4):1042-1045.
10. Calverley PM, Burge PS, Spencer S, Anderson JA, Jones PW. Bronchodilator reversibility testing in chronic obstructive pulmonary disease. Thorax 2003; 58(8):659-664.
11. Douma WR, de Gooijer A, Rijcken B, Schouten JP, Koeter GH, Weiss ST, Postma DS. Lack of correlation between bronchoconstrictor response and bronchodilator response in a population-based study. Eur Respir J 1997; 10(12):2772-2777.
12. Anthonisen NR, Lindgren PG, Tashkin DP, Kanner RE, Scanlon PD, Connett JE. Bronchodilator response in the lung health study over 11 yrs. Eur Respir J 2005; 26(1):45-51.
13. Hansen EF, Vestbo J. Bronchodilator reversibility in COPD: the roguish but harmless little brother of airway hyperresponsiveness? Eur Respir J 2005; 26(1):6-7.
14. Johannessen A, Omenaas ER, Bakke PS, Gulsvik A. Implications of reversibility testing on prevalence and risk factors for chronic obstructive pulmonary disease: a community study. Thorax 2005; 60(10):842-847.
15. Menezes AM, Victora CG, Perez-Padilla R. The Platino project: methodology of a multicenter prevalence survey of chronic obstructive pulmonary disease in major Latin American cities. BMC Med Res Methodol 2004; 4(1):15.
16. Menezes AM, Perez-Padilla R, Jardim JR, Muino A, Lopez MV, Valdivia G, Montes de Oca M, Talamo C, Hallal PC, Victora CG. Chronic obstructive pulmonary disease in five Latin American cities (the PLATINO study): a prevalence study. Lancet 2005; 366(9500):1875-1881.
17. Perez-Padilla R, Valdivia G, Muino A, Lopez MV, Marquez MN, Montes de Oca M, Talamo C, Lisboa C, Pertuze J, B. J. JR, B. M. AM. Spirometric reference values in 5 large Latin American cities for subjects aged 40 years or over. Arch Bronconeumol 2006; 42(7):317-325.
18. American Thoracic Society. Standardization of Spirometry, 1994 Update. Am J Respir Crit Care Med 1995; 152(3):1107-1136.
19. Miller MR., Hankinson J, Brusasco V, Burgos F, Casaburi R, Coates A, Crapo R, Enright P, van der Grinten CP, Gustafsson P, Jensen R, Johnson DC, MacIntyre N, McKay R, Navajas D, Pedersen OF, Pellegrino R, Viegi G,Wanger J. Standardisation of spirometry. Eur Respir J 2005; 26(2):319-338.
20. Borrill ZL, Houghton CM, Woodcock AA, Vestbo J, Singh D. Measuring bronchodilation in COPD clinical trials. Br J Clin Pharmacol 2005; 59(4):379-384.
21. Lehmann S, Bakke PS, Eide GE, Humerfelt S, Gulsvik A. Bronchodilator reversibility testing in an adult general population; the importance of smoking and anthropometrical variables on the response to a beta(2)-agonist. Pulm Pharmacol Ther 2006; 19(4):272-280.
22. Johannessen A, Lehmann S, Omenaas ER, Eide GE, Bakke PS, Gulsvik A. Post-bronchodilator spirometry reference values in adults and implications for disease management. Am J Respir Crit Care Med 2006, Jun 15; 173(12):1316-1325.
23. American Thoracic Society. Lung function testing: selection of reference values and interpretative strategies. American Thoracic Society. Am Rev Respir Dis 1991; 144(5):1202-1218.
24. Ferguson GT, Enright PL, Buist AS, Higgins MW. Office spirometry for lung health assessment in adults: a consensus statement from the National Lung Health Education Program. Chest 2000; 117(4):1146-1161.
25. Hankinson JL, Odencrantz JR, Fedan KB. Spirometric reference values from a sample of the general U.S. population. Am J Respir Crit Care Med 1999; 159(1):179-187.
26. StataCorp. Stata Statistical Software: release 9.0 Stata Corporation, College Station, TX, USA 2005.
27. Cerveri I, Dore R, Corsico A, Zoia MC, Pellegrino R, Brusasco V, Pozzi E. Assessment of emphysema in COPD: a functional and radiologic study. Chest 2004; 125(5):1714-1718.
28. Newton MF, O'Donnell DE, Forkert L. Response of lung volumes to inhaled salbutamol in a large population of patients with severe hyperinflation. Chest 2002; 121(4):1042-1050.
29. O'Donnell DE, Forkert L,Webb KA. Evaluation of bronchodilator responses in patients with "irreversible" emphysema. Eur Respir J 2001; 18(6):914-920.
30. Cerveri I, Pellegrino R, Dore R, Corsico A, Fulgoni P, van de Woestijne KP, Brusasco V. Mechanisms for isolated volume response to a bronchodilator in patients with COPD. J Appl Physiol 2000; 88(6):1989-1995.
31. Barros MJ, Rees PJ. Bronchodilator responses to salbutamol followed by ipratropium bromide in partially reversible airflow obstruction. Respir Med 1990; 84(5):371-375.
32. McIvor RA, Tashkin DP. Underdiagnosis of chronic obstructive pulmonary disease: a rationale for spirometry as a screening tool. Can Respir J 2001; 8(3):153-158.
33. Takahashi T, Ichinose M, Inoue H, Shirato K, Hattori T, Takishima T. Underdiagnosis and undertreatment of COPD in primary care settings. Respirology 2003; 8(4):504-508.
34. Dal Negro R, Rossi A, Cerveri I. The burden of COPD in Italy: results from the Confronting COPD survey. Respir Med 2003; 97 Suppl C:S43-50.
35. Johannessen A, Omenaas E, Bakke P, Gulsvik A. Incidence of GOLD-defined chronic obstructive pulmonary disease in a general adult population. Int J Tuberc Lung Dis 2005; 9(8):926-932.
36. Wilt T, Niewoehner DE, Kim C, Kane RL, Linabery A, Tacklind J, MacDonald R, Rutks I. Use of spirometry for case finding, diagnosis, and management of Chronic Obstructive Pulmonary Disease. Summary. Agency for Healthcare Research and Quality, Rockville, MD, 2005.
37. Boushey H, Enright P, Samet J. Spirometry for chronic obstructive pulmonary disease case finding in primary care? Am J Respir Crit Care Med 2005; 172(12):1481-1482.
38. Celli BR, Halbert RJ, Isonaka S, Schau B. Population impact of different definitions of airway obstruction. Eur Respir J 2003; 22(2):268-273.
39. Hardie JA, Buist AS, Vollmer WM, Ellingsen I, Bakke PS, Morkve O. Risk of over-diagnosis of COPD in asymptomatic elderly never-smokers. Eur Respir J 2002; 20(5):1117-1122.
40. Hnizdo E, Glindmeyer HW, Petsonk EL, Enright P, Buist SA. Case definitions for Chronic Obstructive Pulmonary Disease. COPD: Journal of Chronic Obstructive Pulmonary Disease 2006; 3:95-100.
41. Viegi G, Pedreschi M, Pistelli F, Di Pede F, Baldacci S, Carrozzi L, Giuntini C. Prevalence of airways obstruction in a general population: European Respiratory Society vs American Thoracic Society definition. Chest 2000; 117(5 Suppl 2):339S-45S.
42. Celli BR, Halbert RJ, Nordyke RJ, Schau B. Airway obstruction in never smokers: results from the Third National Health and Nutrition Examination Survey. Am J Med 2005; 118(12):1364-1372.
43. Celli BR, Calverley PM, Rennard SI, Wouters EF, Agusti A, Anthonisen N, Macnee W, Jones P, Pride N, Rodriguez-Roisin R, Rossi A, Wanner A. Proposal for a multidimensional staging system for chronic obstructive pulmonary disease. Respir Med 2005; 99(12):1546-1554.